MA20150030A1 - Compositions and methods for treating hepatitis c virus - Google Patents
Compositions and methods for treating hepatitis c virusInfo
- Publication number
- MA20150030A1 MA20150030A1 MA37130A MA37130A MA20150030A1 MA 20150030 A1 MA20150030 A1 MA 20150030A1 MA 37130 A MA37130 A MA 37130A MA 37130 A MA37130 A MA 37130A MA 20150030 A1 MA20150030 A1 MA 20150030A1
- Authority
- MA
- Morocco
- Prior art keywords
- virus
- subject
- effective amount
- methods
- relates
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 241000711549 Hepacivirus C Species 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 229960000329 ribavirin Drugs 0.000 abstract 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une composition et une forme galénique unitaire pour traiter une infection par le virus de l'hépatite c (hcv) comprenant gs-7977 et au moins un excipient pharmaceutiquement acceptable. L'invention concerne également des procédés pour produire cette composition et cette forme galénique unitaire. Cette invention concerne aussi une méthode pour traiter un sujet, de préférence un être humain, infecté par le virus de l'hépatite c, ladite méthode consiste notamment à administrer au sujet, pendant une période de temps, une quantité efficace de gs -7977 et une quantité efficace de ribavirine. Selon un aspect de l'invention, la méthode consiste notamment à administrer au sujet un schéma thérapeutique exempt d'interféron, qui comprend une quantité efficace de gs-7977 et une quantité efficace de ribavirine. Selon un aspect spécifique, le procédé suffit à produire une quantité non détectable de hcv rna chez le sujet pendant au moins 12 semaines après la fin de la période de temps.The invention relates to a composition and unit dosage form for treating a hepatitis c virus (hcv) infection comprising gs-7977 and at least one pharmaceutically acceptable excipient. The invention also relates to methods for producing this composition and unit dosage form. The invention also relates to a method for treating a subject, preferably a human being, infected with the hepatitis c virus, said method including administering to the subject, for a period of time, an effective amount of gs -7977 and an effective amount of ribavirin. According to one aspect of the invention, the method includes administering to the subject a therapeutic regimen free of interferon, which comprises an effective amount of gs-7977 and an effective amount of ribavirin. In a specific aspect, the method is sufficient to produce an undetectable amount of hcv rna in the subject for at least 12 weeks after the end of the time period.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/661,509 US20130109647A1 (en) | 2011-10-31 | 2012-10-26 | Methods and compositions for treating hepatitis c virus |
| PCT/US2012/066605 WO2013082003A1 (en) | 2011-11-29 | 2012-11-27 | Compositions and methods for treating hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA20150030A1 true MA20150030A1 (en) | 2015-01-30 |
Family
ID=54337492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37130A MA20150030A1 (en) | 2012-10-26 | 2012-11-27 | Compositions and methods for treating hepatitis c virus |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA20150030A1 (en) |
-
2012
- 2012-11-27 MA MA37130A patent/MA20150030A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501133A1 (en) | Compositions and methods for treating hepatitis c virus | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| MY160130A (en) | Hepatitis c virus inhibitors | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| IL207468A (en) | Hcv inhibitors and use thereof for the preparation of medicaments for treatment of hcv infections | |
| EA200900154A1 (en) | PHOSPHATE COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION ON THEIR BASIS, METHOD OF TREATING VIRAL HEPATITIS WITH ITSELVES, THERAPEUTIC MEANS ON THEIR BASIS AND NUMBER NUMBER NUMBER OF THE FOUNDATIONS OF THE VEHICLES OF THEIR BASIC RESEARCHES CHAPTERS CHAPTER | |
| ZA200805304B (en) | Anti-viral compounds | |
| TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
| EP2555622A4 (en) | Hepatitis c virus inhibitors | |
| EA201591702A1 (en) | COMBINATION OF TWO ANTI-VIRAL PREPARATIONS FOR THE TREATMENT OF HEPATITIS C | |
| EA200970375A1 (en) | CONNECTIONS AND METHODS OF TREATMENT OF HEPATITIS C VIRUS | |
| BR112014010295A2 (en) | methods and compositions for the treatment of hepatitis c virus | |
| PL2186830T3 (en) | Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof | |
| MX2010008108A (en) | Heteroaryl-containing tripeptide hcv serine protease inhibitors. | |
| MA20150030A1 (en) | Compositions and methods for treating hepatitis c virus | |
| RU2013120345A (en) | NEW METHODS FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS | |
| RU2009104066A (en) | PREVENTIVE OR THERAPEUTIC AGENT AGAINST VIRAL DISEASE | |
| RU2008138124A (en) | METHOD FOR PREVENTION AND TREATMENT OF DISEASES CAUSED BY HUMAN SUBSTYPE H5N1 VIRUS INFLUENZA VIRUS USING INTERFERON INDUCTOR AND NEURAMINIDASE INHIBITOR | |
| MX2022006414A (en) | TRIPLE VACCINE AGAINST AVIBACTERIUM PARAGALLINARUM AND THE AVIAN ENCEPHALOMYELITIS VIRUS AND THE AVIAN POX VIRUS. | |
| MY187735A (en) | Compositions and methods for treating hepatitis c virus | |
| UA114097C2 (en) | COMPOSITION (OPTIONS) AND METHOD (OPTIONS) OF TREATMENT OF VIRAL HEPATITIS C | |
| EA201892732A1 (en) | ANTI-VIRUS AGENTS FOR THE TREATMENT OF HEPATITIS B | |
| TW200738707A (en) | Anti-viral compounds |